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Abstract 
Background: Schizophrenia is a widespread and debilitating mental disorder. However, the underlying molecular 
mechanism of schizophrenia remains largely unknown and no objective laboratory tests are available to diagnose this 
disorder. The aim of the present study was to characterize the alternations of glucose metabolites and identify poten‑
tial diagnostic biomarkers for schizophrenia.
Methods: Gas chromatography/mass spectrometry based targeted metabolomic method was used to quantify the 
levels of 13 glucose metabolites in peripheral blood mononuclear cells (PBMCs) derived from healthy controls, schizo‑
phrenia and major depression subjects (n = 55 for each group).
Results: The majority (84.6%) of glucose metabolites were significantly disturbed in schizophrenia subjects, while 
only two (15.4%) glucose metabolites were differently expressed in depression subjects relative to healthy controls 
in both training set (n = 35/group) and test set (n = 20/group). Antipsychotics had only a subtle effect on glucose 
metabolism pathway. Moreover, ribose 5‑phosphate in PBMCs showed a high diagnostic performance for first‑epi‑
sode drug‑naïve schizophrenia subjects.
Conclusion: These findings suggested disturbance of glucose metabolism may be implicated in onset of schizophre‑
nia and could aid in development of diagnostic tool for this disorder.
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Background
Schizophrenia is a multifaceted and devastating mental 
disorder affecting up to 1% of the general population [1]. 
It causes progressive functional decline, lifelong disabil-
ity and tremendous socioeconomic burden for patients 
[2, 3]. Despite extensive researches into schizophrenia, 
the definite pathogenesis of schizophrenia remains 
largely unknown. Currently, diagnosis of schizophrenia 
primarily relies on subjective identification of symptom 
clusters by psychiatrist. However, this subjective diag-
nostic modality results in a considerable error rate due 
to the complex spectrum of symptoms and their similari-
ties to other mental disorders [4]. In light of these facts, 
it is greatly needed to explore the molecular mecha-
nism and develop objective diagnostic biomarkers for 
schizophrenia.
Metabolites represent the final product of interactions 
among various factors including genetic, physiological 
and environmental factors, and may better reflect the 
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functional status of individuals. Quantifiable differences 
in metabolite patterns provide valuable clues to uncover 
the mechanism and develop diagnostic biomarkers for 
psychiatry disorders [5, 6]. Recently, our group has char-
acterized metabolite signatures associated with stress 
resilience and suicide [7, 8]. Besides, we have identified 
diagnostic metabolite biomarkers for major depression 
and bipolar disorder [9, 10].
As to schizophrenia, early studies have identified dis-
turbances of several metabolic pathways, such as oxida-
tive stress, lipid and amino acid metabolism [11–13]. 
Specially, it was repeatedly reported that schizophrenia 
patients showed disturbance of several glucose metab-
olite intermediates in periphery and brain [14–16]. 
Transcriptomics and proteomics studies also displayed 
abnormal expression of glucose metabolism-related 
enzymes [17, 18]. Moreover, glucose regulation is related 
to verbal declarative memory performance in schizo-
phrenia patients [19]. These scattered evidences indi-
cated glucose metabolic pathway may be disturbed in 
schizophrenia. However, currently there has not been a 
comprehensive global evaluation of glucose metabolic 
pathway in schizophrenia. More importantly, it remains 
unclear whether and how specific changes of glucose 
metabolism might account for schizophrenia.
Brain tissues and cerebrospinal fluid seem to be 
the most suitable biological samples for schizophre-
nia research. However, brain tissue biopsy and lumbar 
puncture cannot be practically applied in schizophrenia 
patients due to ethical and safety constraints. In contrast, 
peripheral blood mononuclear cells (PBMCs) can be eas-
ily collected at minimal risk and cost and allow to capture 
the freshly isolated systemic cellular reactivity in the early 
phases of the disorder [20]. Besides, PBMCs may reflect 
molecular processes in the central nervous system as the 
brain and PBMCs show a number of parallel responses 
[21–23]. Moreover, peripheral immune dysfunction was 
widely implicated in the pathogenesis of schizophrenia 
[24, 25]. Significantly, previous studies have indicated 
that such cells are useful peripheral sources to identify 
the underlying pathogenic mechanisms and diagnostic 
markers for other psychiatric disorders such as autism, 
depression and borderline personality disorder [26–28]. 
Considering the above information, PBMCs were thus 
chosen as the sample source in this study.
Here, using a gas chromatography/mass spectrometry 
(GC/MS) based targeted metabolomic method, we simul-
taneously quantified the levels of 13 glucose metabolites 
in PBMCs derived from schizophrenia, major depres-
sion and healthy control groups (n = 55 for each group). 
Our aim was to characterize how the glucose metabolites 
change in the early stage of schizophrenia, and identify 
the potential diagnostic PBMC metabolite biomarkers 
for schizophrenia. Besides, we sought to determine 




Prior to sample collection, written informed consents 
were obtained from all recruited subjects. The protocols 
of this study were reviewed and approved by the Ethical 
Committee of Chongqing Medical University. All pro-
cedures were conducted according to the principles 
expressed in the Declaration of Helsinki.
Participants
Totally, 55 schizophrenia and 55 major depression sub-
jects were recruited from the psychiatric center in the 
First Affiliated Hospital of Chongqing Medical Uni-
versity. All diagnoses were performed according to the 
Structured Psychiatric Interview using the DSM-IV-TR 
criteria [29]. Candidates with pre-existing physical or 
other mental disorders, or illicit drug use were excluded. 
During the same time period, 55 healthy controls were 
enrolled from the medical examination center in the First 
Affiliated Hospital of Chongqing Medical University. 
Healthy controls were required to have no current or pre-
vious lifetime history of neurological, DSM-IV Axis I/II, 
or systemic medical illness.
The recruited samples were divided into a training set 
and a test set. The training set, comprising healthy con-
trols, first-episode drug-naïve schizophrenia and major 
depression subjects (n = 35/group), was used to charac-
terize the unique glucose metabolic pattern and identify 
the potential diagnostic markers for schizophrenia. The 
test set, comprising 20 schizophrenia subjects, 20 major 
depression subjects and 20 healthy controls, was used to 
independently validate the identified glucose metabolic 
pattern of schizophrenia and assess the effect of antipsy-
chotics on glucose metabolites.
Sample preparation and GC/MS acquisition
Fasting blood samples were collected into EDTA-coated 
tubes and were centrifuged at 3,000  rpm for 15  min at 
4°C to obtain plasma. Subsequently plasm was overlaid 
onto Ficoll-Paque Plus (GE Healthcare Bio-sciences AB, 
Sweden), and centrifuged at 2,000  rpm for 20  min at 
room temperature. The purified PBMCs were harvested 
and washed three times in phosphate buffer saline. After 
that, each PBMC sample was divided into equal aliquots, 
transferred into liquid nitrogen for 3 min and then stored 
at −80°C until undergoing later analysis.
For GC–MS analysis, each aliquot of PBMCs, which 
was isolated from 5 ml blood sample, was added with a 
400  μL solution of water–methanol–chloroform (2:5:2, 
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v/v/v). After vortexing for 30 s and standing overnight at 
−20°C, the mixture was sonicated for 3 min and subse-
quently centrifuged at 14,000g for 10 min at 4°C. 300 μL 
supernatant was collected, and the residue was resus-
pended in 200 μL methanol. The residue was then vor-
texed and centrifugated as before. 200  μL supernatant 
of the residue was extracted and mixed with the first. A 
250 μL aliquot of mixed supernatant was evaporated to 
dryness under a stream of nitrogen gas. The dried meta-
bolic extract was derivatized first with 30 µL of methox-
amine (20  mg/mL) for 90  min at 37°C with continuous 
shaking. Subsequently, 30  µL of BSTFA with 1% TCMS 
was added to the mixture and heated for 1 h at 70°C to 
form trimethylsilyl (TMS) derivatives. After derivatiza-
tion and cooling to room temperature, 1 μL of this deriv-
ative was injected in the GC/MS for analysis.
GC/MS analysis
GC/MS analysis was carried out according to this group’s 
previously published work [7, 30]. Briefly, each 1 μL of the 
derived sample was injected into an Agilent 7890A GC 
system (Agilent Technologies Inc., USA). An HP-5 MS 
fused silica capillary column (30 m × 0.25 mm × 0.25 μm, 
Agilent, USA) was used for metabolite separation with 
helium carrier gas at a flow rate of 1 mL/min. The injec-
tor temperature was set at 280°C. The column temperature 
was initially kept at 80°C for 2 min and then increased to 
320°C at 10°C/min, where it was held for 6 min. The col-
umn effluent was introduced into the ion source of an Agi-
lent 5975 mass selective detector (Agilent Technologies). 
The MS quadrupole temperature was set at 150°C, and the 
ion source temperature was set at 230°C. Data acquisition 
was performed first in the full-scan mode (scanning range 
from 50 to 550 m/z) and then in selected ion monitoring 
(SIM) mode for quantification. The characteristic frag-
ment ions and retention times of metabolites were shown 
in Additional file  1: Table S1. All samples were analyzed 
consecutively at random. A quality control (QC) sam-
ple, pooled from a representative PBMCs sample of each 
group, was added in each batch of analyses in order to 
adjust the variations between batch variability.
Targeted metabolomic data analysis
Mass spectral data were converted to NetCDF format 
and then processed by XCMS software for peak find-
ing, integration and alignment. The optimized XCMS 
parameters were set as follows: method =  “matchedFil-
ter”; full width at half maximum (fwhm)  =  4.0; signal-
to-noise cutoff (snthresh) = 10.0; retention time window 
(bw) =  3. Each metabolite concentration was expressed 
in relative abundance (metabolite peak area of study sam-
ple divided by that of QC sample) before the following 
statistical analysis.
Identification of PBMC metabolite biomarkers 
for schizophrenia
As clinical diagnosis based on the quantification of a 
small number of metabolites would be more practical, 
a stepwise optimization algorithm based on Akaike’s 
information criterion (AIC) was applied to optimize the 
metabolite biomarker combination [9, 10]. To evaluate 
the diagnostic generalizability of the schizophrenia bio-
marker, the ability of the simplified biomarker panel to 
discriminate schizophrenia subjects from non-schizo-
phrenia subjects was quantified using a receiver-operat-
ing characteristic (ROC) curve analysis [31].
Statistical analysis
The Chi square test was applied to analyze categorical 
data (sex). All continuous variables such as age, BMI and 
metabolite concentrations were analyzed using one-way 
ANOVA followed by Bonferroni post hoc test. All con-
tinuous variables were expressed as means  ±  standard 
errors of the mean. The statistical analyses were carried 
out with SPSS software (version 17.0). A p value of less 
than 0.05 was considered to be statistically significant.
Results
Demographic and clinical characteristics
The detailed demographic and clinical characteristics 
of the recruited subjects are presented in Table  1. The 
demographic parameters such as age, gender and BMI 
were not distinguishable among these three groups in 
both training set and test set.
Characterization of differentially expressed metabolites 
between schizophrenia subjects and healthy controls
Using GC–MS approach, we measured 13 key metabo-
lites of glucose metabolism pathways in PBMCs. In 
training set, 11 metabolites (84.6%) were differentially 
expressed in first-episode drug-naïve schizophrenia 
subjects relative to healthy controls (Table  2; Figure  1). 
Thereinto, seven metabolites were significantly increased 
in schizophrenia subjects relative to healthy controls, 
including glucose, glucose 6-phosphate, fructose, fruc-
tose 6-phosphate, glycerate 3-phosphate, succinic acid 
and ribose 5-phosphate. Moreover, four metabolites were 
significantly decreased in schizophrenia subjects relative 
to healthy controls, including glyceraldehyde-3-phos-
phate, dihydroxyacetone phosphate, glycerol 3-phosphate 
and citric acid. The remaining metabolites, pyruvate and 
lactic acid, did not differ between these two groups.
Additionally, the results aforementioned could be repli-
cated in independent test set except for four metabolites, 
including glycerate 3-phosphate, pyruvate, lactic acid 
and ribose 5-phosphate (Table  2). In detail, compared 
to healthy controls, levels of glycerate 3-phosphate and 
Page 4 of 9Liu et al. J Transl Med  (2015) 13:226 
ribose 5-phosphate in schizophrenia subjects were sig-
nificantly higher in training set, but did not differ in test 
set. On the contrary, relative to healthy controls, levels of 
pyruvate and lactic acid in schizophrenia subjects were 
not distinguishable in training set, but were significantly 
differently expressed in test set.
To test whether antipsychotics influenced glucose 
metabolism, we compared levels of glucose metabo-
lites between unmedicated and medicated schizophre-
nia subjects in test set (Additional file  1: Table  S2). Of 
these 13 metabolites, only ribose 5-phosphate were dif-
ferently expressed between unmedicated and medicated 
schizophrenia subjects. These findings demonstrated that 
antipsychotics may not significantly influence glucose 
metabolism in individuals with episode schizophrenia.
Characterization of differentially expressed metabolites 
between depression subjects and healthy controls
In opposite to schizophrenia, only 2 of 13 (15.4%) glu-
cose metabolites were differently expressed between 
Table 1 Demographic characteristics of the recruited subjects
Chi square analyses for categorical variables (sex).
SZ schizophrenia, MD major depression, HC healthy controls, M/F male/female.
a ANOVA test for continuous variable (age, BMI).
b Values were expressed as mean ± SEM.
Variables SZ MD HC Statistics Pa
Training set Sample size 35 35 35 – –
Medication (Y/N) N N N – –
Sex (M/F) 14/21 17/18 18/17 χ2 = 1.00 0.61
Age (years)b 32.49 ± 14.12 36.40 ± 10.65 36.54 ± 5.98 F = 1.60 0.21
BMIb 22.60 ± 1.95 22.09 ± 2.12 22.21 ± 1.72 F = 0.67 0.52
Test set Sample size 20 20 20 – –
Medication (Y/N) 6/14 N N – –
Sex (M/F) 9/11 11/9 10/10 χ2 = 0.40 0.82
Age (years)b 28.45 ± 2.09 27.55 ± 2.05 30.15 ± 1.65 F = 0.47 0.63
BMIb 21.86 ± 0.50 21.70 ± 0.55 21.74 ± 0.48 F = 0.03 0.98
Table 2 The differentially expressed metabolites between SZ and HC group
Values given in bold denote statistically significant results (P < 0.05).
SZ schizophrenia, HC healthy controls, FC fold change, TCA tricarboxylic acid cycle.
a A negative log2(FC) indicated significantly lower expression in schizophrenia subjects compared to healthy controls; a positive log2(FC) indicated significantly higher 
expression in schizophrenia subjects compared to healthy controls.
b These data were analyzed using one-way ANOVA followed by Bonferroni post hoc test between two groups of each cohort.
Metabolites Metabolic pathway Training set Test set
Log2(FC)
a P valueb Log2(FC)
a P valueb
Glucose Glycosis 4.22 0.000 0.67 0.000
Glucose 6‑phosphate Glycosis 1.84 0.000 1.48 0.000
Fructose 6‑phosphate Glycosis 1.84 0.000 1.06 0.000
Fructose Glycosis 6.12 0.000 0.48 0.003
Glyceraldehyde‑3‑phosphate Glycosis −1.91 0.000 −1.05 0.006
Dihydroxyacetone phosphate Glycosis −2.28 0.000 −1.28 0.000
Glycerol 3‑phosphate Glycosis −0.6 0.000 −0.49 0.001
Glycerate 3‑phosphate Glycosis 0.88 0.000 0.28 0.363
Pyruvate Glycosis 0.54 0.090 0.82 0.013
Lactic acid Glycosis −0.11 1.000 −0.79 0.002
Citric acid TCA −1.08 0.000 −0.71 0.001
Succinic acid TCA 3.08 0.000 0.76 0.001
Ribose 5‑phosphate Pentose phosphate pathway 4.53 0.000 −0.39 0.133
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depression subjects and healthy controls in both train-
ing set and test set (Table  3; Figure  1). The majority of 
results were consistent in both sets. Specifically, fruc-
tose 6-phosphate was significantly increased in depres-
sion subjects relative to healthy controls in training set, 
but were not distinguishable between these two groups 
in test set. Compared to healthy controls, dihydroxyac-
etone phosphate in depression subjects were significantly 
increased in training set, but decreased in test set. More-
over, compared to healthy controls, levels of succinic acid 
in depression subjects were not distinguishable in train-
ing set, but were significantly increased in test set.
Characterization of differentially expressed metabolites 
between schizophrenia and depression subjects
In training set, 11 of 13 glucose metabolites were dif-
ferently expressed between schizophrenia and depres-
sion subjects (Table  4). Coincidentally, these 11 altered 
metabolites were also differently expressed between 
schizophrenia subjects and healthy controls in training 
set.
In test set, only five metabolites were consistently dif-
ferently expressed between schizophrenia and depression 
subjects (Table  4). However, the changes of other five 
metabolites (glucose, fructose, glyceraldehyde-3-phos-
phate, dihydroxyacetone phosphate and succinic acid) in 
test set showed the same trend as those in training set, 
although did not reach statistical significance.
These results demonstrated the glucose metabolic sig-
nature of schizophrenia subjects in PBMCs was signifi-
cantly distinguishable from that of non-schizophrenia 
subjects.
A potential diagnostic biomarker for schizophrenia
Although unique glucose metabolic pattern provided great 
potential for diagnosis of schizophrenia, measurements of 
all glucose metabolites were not convenient and economi-
cal in clinical. To identify a simplified diagnostic biomarker 
for schizophrenia, a step-wise optimization algorithm 
based on AIC was applied. The statistical analysis dem-
onstrated that ribose 5-phosphate which involved in pen-
tose phosphate pathway showed the highest diagnostic 
Figure 1 Differential metabolites and metabolic enzymes involved in glucose metabolism. All these metabolites were compared among three 
groups in training set. Red-colored boxes indicate increased metabolites in schizophrenia or major depression subjects compared to healthy controls, 
while green-colored boxes indicate decreased metabolites; Red letters indicate upregulated metabolic enzymes in PBMCs of schizophrenia subjects 
as previous proteomic study reported [18]. ALDOC aldolase C, TPIS triosephosphate isomerase, GAPDH glyceraldehydes‑3‑phosphate dehydroge‑
nase, PGK1 phosphoglycerate kinase 1, PGAM2 phosphoglycerate mutase 2, PKL pyruvate kinase, LDHB lactate dehydrogenase B.
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performance in identifying first-episode drug-naïve schiz-
ophrenia subjects in training set. The area under ROC 
curve (AUC) was 1.00 in discriminating schizophrenia 
subjects from healthy controls or major depression sub-
jects in training set. As an AUC of 1 indicates perfect 
discrimination, these results demonstrated that ribose 
5-phosphate in PBMCs may be a potential biomarker for 
first-episode drug-naïve schizophrenia subjects.
We found that ribose 5-phosphate was consist-
ently increased in unmedicated schizophrenia subjects 
Table 3 The differentially expressed metabolites between MD and HC group
Values given in bold denote statistically significant results (P < 0.05).
MD major depression, HC healthy controls, FC fold change, TCA tricarboxylic acid cycle.
a A negative log2(FC) indicated significantly lower expression in major depressive subjects compared to healthy controls; a positive log2(FC) indicated significantly 
higher expression in major depressive subjects compared to healthy controls.
b These data were analyzed using one-way ANOVA followed by Bonferroni post hoc test between two groups of each cohort.
Metabolites Metabolic pathway Training set Test set
Log2(FC)
a P valueb Log2(FC)
a P valueb
Glucose Glycosis 0.50 1.000 0.34 0.239
Glucose 6‑phosphate Glycosis 0.74 0.228 0.38 1.000
Fructose 6‑phosphate Glycosis 0.99 0.019 0.18 1.000
Fructose Glycosis 0.08 1.000 0.29 0.198
Glyceraldehyde‑3‑phosphate Glycosis −0.09 0.907 −0.25 0.802
Dihydroxyacetone phosphate Glycosis 0.71 0.000 −0.79 0.004
Glycerol 3‑phosphate Glycosis −0.09 1.000 −0.10 1.000
Glycerate 3‑phosphate Glycosis −0.71 0.190 −0.28 0.692
Pyruvate Glycosis 0.34 0.606 0.22 1.000
Lactic acid Glycosis −0.15 1.000 −0.31 0.239
Citric acid TCA −0.09 1.000 −0.11 1.000
Succinic acid TCA 0.07 1.000 0.71 0.003
Ribose 5‑phosphate Pentose phosphate pathway −0.03 1.000 −0.16 1.000
Table 4 The differentially expressed metabolites between SZ and MD group
Values given in bold denote statistically significant results (P < 0.05).
SZ schizophrenia, MD major depression, FC fold change, TCA tricarboxylic acid cycle.
a A negative log2(FC) indicated significantly lower expression in schizophrenia subjects compared to major depressive subjects; a positive log2(FC) indicated 
significantly higher expression in schizophrenia subjects compared to major depressive subjects.
b These data were analyzed using one-way ANOVA followed by Bonferroni post hoc test between two groups of each cohort.
Metabolites Metabolic pathway Training set Test set
Log2(FC)
a P valueb Log2(FC)
a P valueb
Glucose Glycosis 3.73 0.000 0.32 0.071
Glucose 6‑phosphate Glycosis 1.09 0.000 1.10 0.000
Fructose 6‑phosphate Glycosis 0.85 0.000 0.88 0.001
Fructose Glycosis 6.04 0.000 0.19 0.342
Glyceraldehyde‑3‑phosphate Glycosis −1.83 0.000 −0.80 0.114
Dihydroxyacetone phosphate Glycosis −2.99 0.000 −0.49 0.849
Glycerol 3‑phosphate Glycosis −0.52 0.000 −0.39 0.020
Glycerate 3‑phosphate Glycosis 1.59 0.000 0.56 0.022
Pyruvate Glycosis 0.2 1.000 0.60 0.057
Lactic acid Glycosis 0.04 1.000 −0.48 0.198
Citric acid TCA −0.98 0.000 −0.60 0.008
Succinic acid TCA 3.01 0.000 0.06 1.000
Ribose 5‑phosphate Pentose phosphate pathway 4.56 0.000 −0.23 0.820
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relative to healthy controls in both training set and test 
set. However, levels of ribose 5-phosphate in medicated 
schizophrenia subjects was significantly lower than 
healthy controls in test set (Additional file  1: Table  S2). 
This findings indicated that antipsychotics could reduce 
the diagnostic performance of ribose 5-phosphate for 
schizophrenia.
Discussion
Schizophrenia is a widespread and debilitating mental 
disorder. Current diagnosis of schizophrenia remains 
subjective, and the underlying molecular mechanisms 
remains largely unknown. Here, we found that major-
ity of glucose metabolites in PBMCs were disturbed in 
schizophrenia subjects, which was in contrast to the find-
ings of depression subjects. Furthermore, ribose 5-phos-
phate showed the highest diagnostic performance for 
first-episode drug-naïve schizophrenia subjects among 
the identified glucose metabolites. These results suggest 
that disturbance of glucose metabolism pathway may be 
implicated in the onset of schizophrenia, and may have 
utility in diagnosis of schizophrenia.
Antipsychotic medication and demographic factors 
(such as age, sex, obesity) were considered as possible 
confounders affecting the glucose metabolism [32, 33]. 
We circumvented this problem by carrying out analyses 
of PBMCs samples from first-episode drug-naïve schizo-
phrenia subjects and demographic-matched controls. 
Hence, in this study, the glucose metabolism pattern of 
schizophrenia subjects might truly reflect the patho-
physiologic changes inherent in the schizophrenia dis-
ease state. Consistent with these findings, several studies 
have also revealed poor glucose regulation and abnormal 
expressions of glucose metabolism related molecules in 
unmedicated schizophrenia subjects [12, 18, 20]. Differ-
ent from previous studies, we found that antipsychotics 
had only a subtle effect on glucose metabolites in PBMCs 
except ribose 5-phosphate in this study. The discrepancy 
with our results may be due to the more stable micro-
environment in PBMCs than peripheral body fluids and 
antipsychotic drug-sensitive tissues.
Glucose is mainly metabolized via the glycolytic 
pathway and TCA cycle to provide energy and biosyn-
thetic intermediates. Glucose metabolism homeostasis 
is fundamental to maintain normal brain functions. In 
this study, of the 12 metabolites relevant to glycolysis 
and TCA cycle, 50% metabolites were increased while 
only 33.3% metabolites were decreased in first-episode 
drug-naïve schizophrenia subjects compared to healthy 
controls. In concordance with this finding, a recent pro-
teomics study reported that majority (87.5%) of glucose 
metabolic enzymes in PBMCs were significantly ele-
vated in first-episode drug-naïve schizophrenia subjects 
relative to healthy controls [18]. Besides, several glucose 
metabolic enzymes such as aldolase C, triosephosphate 
isomerase, glyceraldehydes-3-phosphate dehydrogenase, 
phosphoglycerate kinase 1, phosphoglycerate mutase 
were consistently elevated in both brain tissues and 
PBMCs of schizophrenia as described in previous studies 
[16, 34–37]. Combined with these evidences, we deduced 
that glycolysis pathway and TCA cycle may be activated 
in the early stage of schizophrenia onset. Other groups 
have also reported higher levels of ATP and increased 
gene/protein expression associated with glucose metabo-
lism in schizophrenia patients [16, 38, 39], further sup-
porting our findings.
Pentose phosphate pathway is another important 
branch of glucose metabolism that functions in the for-
mation of NADPH for biosynthetic processes and cel-
lular redox balance. Ribose 5-phosphate is the main 
product of this pathway. Here, ribose 5-phosphate was 
increased in PBMCs of first-episode drug-naïve schizo-
phrenia subjects compared to healthy controls, suggest-
ing disturbance of pentose phosphate pathway may play 
an important role in the onset of schizophrenia. In agree-
ment with this speculation, previous studies have also 
reported increased expressions of pentose phosphate 
pathway related molecules in schizophrenia [36, 40].
As disturbances of glucose metabolism have also been 
observed in other psychiatry disorders, such as major 
depression. The question then arises whether disturbance 
of glucose metabolism observed in this study reflects 
schizophrenia-specific pathophysiological changes. To 
elucidate this question, we also recruited first-episode 
drug-naive major depression subjects that shared a num-
ber of factors in common with schizophrenia subjects. 
We found that only few kinds of glucose metabolites 
were differentially expressed in major depression subjects 
compared to healthy controls, reflecting subtle altera-
tions of glucose metabolism pathways in this disorder. 
The results contrast with those of previous studies that 
reported significant disturbances of glucose metabolism 
in major depression subjects [41, 42]. The discrepancy 
may be caused by the differences in sample type, study 
population, antidepressant treatment and detected com-
ponents. Here, we found that majority of glucose metab-
olites were distinguishable between major depression and 
schizophrenia subjects. The results reflected that distinct, 
rather than generalized, glucose metabolic changes exist 
in PBMCs of schizophrenia.
Certain limitations of this study should be noted. 
Firstly, the sample size of first-episode drug-naïve schizo-
phrenia subjects used in this study was relatively small. 
This was limited by the fact that large clinical centers 
(~1,500 patients) recruit only 10–20 antipsychotic-naive 
patients who are free of substance abuse or comorbidities 
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per year. Further studies with larger cohorts should be 
performed to validate these findings, especially with 
regard to the diagnostic performance of ribose 5-phos-
phate in schizophrenia. Secondly, all subjects were of the 
same ethnicity and were recruited from the same site. 
Thus, ethno- and site-specific biases cannot be ruled out. 
Further studies involving heterogeneous populations 
from multiple clinical sites are required.
Conclusion
In this study, we provide evidence that severe disturbance 
of glucose metabolism in PBMCs may be implicated in 
the onset of schizophrenia. Moreover, ribose 5-phosphate 
showed a high diagnostic performance for first-episode 
drug-naïve schizophrenia subjects. These findings will be 
valuable in uncovering the pathogenesis of schizophrenia 
and facilitate to develop diagnostic tools for this disorder.
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